Nicotinamide riboside for COVID-19

Phase-Based Estimates
1
Effectiveness
2
Safety
The University of Texas Health Science Center at San Antonio, San Antonio, TX
COVID-19+2 More
Nicotinamide riboside - Drug
Eligibility
18+
All Sexes
Eligible conditions
COVID-19

Study Summary

This study is evaluating whether a vitamin may help treat a serious infection.

See full description

Eligible Conditions

  • COVID-19
  • Acute Kidney Injury
  • Coronavirus Disease 2019 (COVID‑19)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Nicotinamide riboside will improve 3 primary outcomes and 4 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Baseline to 10 days.

Day 90
Change in Proteinuria
Change in estimated Glomerular Filtration Rate (eGFR)
Effect of NR on Major Adverse Kidney Events (MAKE)
Baseline to 10 days
Change in Area under the curve (AUC)
Change in whole blood NAD+ level
Number of Adverse Events of Grade 3 or Higher
Occurrence of Thrombocytopenia

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Compared to trials

Trial Design

2 Treatment Groups

Placebo Group
Nicotinamide Riboside Group
Placebo group

This trial requires 32 total participants across 2 different treatment groups

This trial involves 2 different treatments. Nicotinamide Riboside is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Nicotinamide Riboside Group
Drug
Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
Placebo Group
Drug
Placebo capsules will be administered 2 capsules twice daily for 10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Not yet FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days to 90 days
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 30 days to 90 days for reporting.

Who is running the study

Principal Investigator
K. S.
Kumar Sharma, Holder of the L. David Hillis, M.D. Endowed Chair, Medicine -Renal Diseases
The University of Texas Health Science Center at San Antonio

Closest Location

The University of Texas Health Science Center at San Antonio - San Antonio, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Provision of signed and dated informed consent form from a participant or legally authorized representative (LAR);
Male or female, >18 years old;
Hospitalized participants with a laboratory diagnosis of COVID-19 infection
Evidence of persistent AKI as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (Table 3);
Willing to adhere to the study intervention regimen;

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes covid-19?

Add answer

Covid-19 is still an active health crisis. On the heels of a new virus outbreak, the CDC aims to provide information on how to diagnose and respond to this potentially serious illness. The goals of this report are to guide health-care professionals in detecting and responding to the disease, to provide up to date information about coronavirus and the coronavirus disease 2019, and to help health providers understand how to ensure safety for patients and health-care workers. https://www.cdc.gov/coronavirus/nCoV20192019/index.

Unverified Answer

What are the signs of covid-19?

Add answer

Symptoms of covid-19 include sudden and severe pain of the throat, with or without fever, and in severe cases a cough that clears up within three to five days. Those with respiratory illness or fever within 14 days before a diagnosis of COVID-19 need to be tested in-depth for the disease to prevent further spread of the virus. It is imperative that patients with these symptoms consult with their doctor. They may be prescribed anti-virals.

Unverified Answer

Can covid-19 be cured?

Add answer

There is good evidence for the efficacy of the drug remdesivir, but the duration of disease is still long and the clinical response to treatment is modest. There is no evidence of a cure of the disease. The available evidence at present seems not to support a cure, but the possibility of a prolonged, clinically-remarkable improvement cannot be ruled out.

Unverified Answer

How many people get covid-19 a year in the United States?

Add answer

About 6 million people have been infected with the coronavirus SARS-CoV-2 /2019-nCoV in the United States as of early July, which will result in around 20,000 to 28,000 deaths due to SARS-CoV-2 / 2019-nCoV infection.\n

Unverified Answer

What are common treatments for covid-19?

Add answer

Patients with covid-19 were at increased risk of having multiple hospital admissions due to heart and lung complications; the most common treatment was fluid administration alone. There is no published evidence to support the use of any specific covid-19 treatments. Patients with covid-19 and mild or moderate hypoxemia often experienced minimal or no benefits from oxygen supplementation in the form of nasal cannula or face mask.

Unverified Answer

What is covid-19?

Add answer

This crisis is not in the least devastating as we believe, but the outbreak of a disease that is already affecting a considerable population, not to mention those, already in a precarious social and economical situation, is going to have an enormous influence on health and the social life of countries around the world. There are new challenges to be faced, so we can say that, as in the past, social health policies and the health and social service activities related to the epidemic must be strengthened. We will have to develop a more global strategy and to increase the knowledge and vigilance about epidemics.

Unverified Answer

Have there been any new discoveries for treating covid-19?

Add answer

There are currently [no medications or vaccine that can treat or prevent covid-19]. However, there are currently [no clinical trials that can prove that any of the aforementioned treatments are efficacious in curing or preventing covid-19]. There have been several clinical trials published lately that try to support the use of antiviral [truncating mutations of NPP3C gene], anti-inflammatory, and IL-6 inhibitor drugs in preventing / treating covid-19. However, these approaches have failed to show an efficacious [in curing or preventing covid-19] and [in clinical trials, show [no statistically significant differences in any of these clinical trials compared to placebo controls] have yet to be used.

Unverified Answer

What is the primary cause of covid-19?

Add answer

Both genetic and environmental factors play an important role in determining an individual's risk of contracting covid-19. This indicates that our current methods of surveillance and intervention are not effective enough to prevent the virus from spreading. These measures should therefore be improved.

Unverified Answer

Have there been other clinical trials involving nicotinamide riboside?

Add answer

There are no studies on nicotinamide riboside, but a few studies supporting its use after bone marrow [transplant](https://www.withpower.com/clinical-trials/transplant)ation (BMT) to treat HCC and CVD, and a study on its use as a prophylactic in MDS. As a supplement and as part of HCC, clinical studies have focused on treating patients with cirrhosis, metastatic disease, and recurrent metastatic disease. Nicotinamide riboside has shown to reduce liver cancer recurrence and prolong overall survival; the mechanism for this efficacy is unknown. One review that summarizes these studies is summarized below.\n\nFor CVD, a systematic review and meta-analysis of 16 randomized clinical trials (RCTs) was performed.

Unverified Answer

What are the latest developments in nicotinamide riboside for therapeutic use?

Add answer

Inhibition of NAD+-dependent glycolysis would be therapeutically attractive as it would have the potential to reduce oxidative stress and thus limit viral proliferation by reducing the demand for ribonucleotides, which otherwise would compete with the virus to use as building blocks. Inhibition of NAD+-dependent glycolysis was recently shown to be efficient in inhibiting viral proliferation in the case of the Zika virus. Data from a recent study demonstrate the use of NAM in the management of the viral disease Zika, and provide rationale for NAM's clinical development for use against other viral infections. Clinical trials of NAM in patients with various indications are currently taking place.

Unverified Answer

How serious can covid-19 be?

Add answer

The health consequences of an acute coronavirus outbreak include increased rates of infection, increased mortality, and greater demands on healthcare. The potential impact of an outbreak, particularly on healthcare provision and services are likely to be significant; however, evidence of such immediate consequences is challenging and more research is required.

Unverified Answer

How does nicotinamide riboside work?

Add answer

Nicotinic acid, nicotinamide riboside, and nicotinamide are all converted to nicotinamide in the liver. These observations, in addition to an [increased] increase in nicotinamide following NAR administration, might be at least partially responsible for NAR-induced improvements in disease severity, muscular strength, and fatigue.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.